An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Docetaxel (Primary) ; Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 03 Oct 2017 Planned End Date changed from 2 Apr 2019 to 12 Jul 2018.
- 03 Oct 2017 Planned primary completion date changed from 2 Apr 2019 to 12 Jul 2018.
- 18 Sep 2017 Planned End Date changed from 29 Jun 2018 to 2 Apr 2019.